MCMariapaola Cucinotta

Mariapaola Cucinotta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariapaola Cucinotta has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • A. Crucitti

    Unit and School of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria n. 1, 98125 Messina, Italy

    1 shared publication
  • Alessandra Bitto

    Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy

    1 shared publication
  • Alfredo Campennì

    Department of Biomedical Sciences and of Morphological and Functional Images, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy

    1 shared publication
  • Alireza Mojtahedi

    Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA

    1 shared publication
  • Angelina Cistaro

    Nuclear Medicine Department, Salus Alliance Medical, 16128 Genoa, Italy

    1 shared publication
  • Antonino Catalano

    Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Oxidative Stress: Harms and Benefits for Human Health

    by Gabriele Pizzino, Natasha Irrera, Mariapaola Cucinotta, Giovanni Pallio, Federica Mannino, Vincenzo Arcoraci, Francesco Squadrito, Domenica Altavilla, Alessandra Bitto

    Oxidative stress is a phenomenon caused by an imbalance between production and accumulation of oxygen reactive species (ROS) in cells and tissues and the ability of a biological system to detoxify these reactive products. ROS can play, and in fact they do it, several physiological roles (i.e., cell signaling), and they are normally generated as by‐products of oxygen metabolism; despite this, environmental stressors (i.e., UV, ionizing radiations, pollutants, and heavy metals) and xenobiotics (i.e., antiblastic drugs) contribute to greatly increase ROS production, therefore causing the imbalance that leads to cell and tissue damage (oxidative stress). Several antioxidants have been exploited in recent years for their actual or supposed beneficial effect against oxidative stress, such as vitamin E, flavonoids, and polyphenols. While we tend to describe oxidative stress just as harmful for human body, it is true as well that it is exploited as a therapeutic approach to treat clinical conditions such as cancer, with a certain degree of clinical success. In this review, we will describe the most recent findings in the oxidative stress field, highlighting both its bad and good sides for human health.


  • Serum levels of Apelin-36 are decreased in older hospitalized patients with heart failure

    by G. Basile, A. Crucitti, Maria Cucinotta, A. Lacquaniti, A. Catalano, S. Loddo, M. Buemi, A. Lasco


  • Open Access

    Is %ΔSUVmax a Useful Indicator of Survival in Patients with Advanced Nonsmall‐Cell Lung Cancer?

    by Angelina Cistaro, Natale Quartuccio, Alireza Mojtahedi, Piercarlo Fania, Pier Luigi Filosso, Mariapaola Cucinotta, Alfredo Campennì, Umberto Ficola, Sergio Baldari

    Purpose. To investigate the impact of the maximum standardized uptake value (SUVmax), size of primary lung lesion, and %ΔSUVmax on outcome (overall survival (OS) and 2‐year disease‐free survival (2‐year DFS)) of patients with advanced nonsmall‐cell lung cancer (NSCLC). Materials and Methods. 86 stage III‐IV NSCLC patients underwent 18 F‐FDGPET/CT, before and after chemotherapy, and were classified into subgroups according to the response criteria of the European Organization for Research and Treatment of Cancer. SUVmax values and tumor size with the best prognostic significance were searched. Correlation between the SUVmax value and the initial response to therapy (best response) and the relationship between %ΔSUVmax and OS were assessed. Results. In patients in PD (20/86), the average pretreatment SUVmax was 11.8 ± 5.23, and the mean size of the primary lesion was 43.35 mm ± 16.63. In SD, PR, and CR patients (66/86), the average pretreatment SUVmax was 12.7 ± 8.05, and the mean size of the primary lesion was 41.6 mm ± 21.15. Correlation was identified only for %ΔSUVmax; patients with PD (ΔSUVmax > +25%) showed a worse OS than patients with ΔSUVmax < +25% (CR, PR, and SD) (P = 0.0235). Conclusions. In stage III‐IV NSCLC, among the assessed factors, only %ΔSUVmax may be considered as a useful prognostic factor.